Patents by Inventor Benjamin Jason Compton

Benjamin Jason Compton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IMMUNOSTIMULATORY COMPOSITIONS
    Publication number: 20250049904
    Abstract: The present application is directed to immunomodulatory compositions comprising invariant NKT cell (iNKT cell) agonist compounds that induce expansion of tissue resident memory T-cells (Trm Cells) in combination with an immune stimulator agent that enhances an immune response to a target antigen or a polynucleotide encoding the immune stimulator. The iNKT agonists are ?-GalCer analogue compounds modified at the 6 position of the galactose ring. The immune stimulator is an antigen or an mRNA encoding an antigen to create a vaccine formulation. These combinations are used in the treatment of infection or cancer in a subject, or to enrich the number of Trm cells in the liver of a subject.
    Type: Application
    Filed: December 22, 2022
    Publication date: February 13, 2025
    Inventors: Gavin Frank Painter, Ian Francis Hermans, Mitch Ganley, William Heath, Lauren Holz, Regan James Anderson, Benjamin Jason Compton, Andrew Marshall
  • Amino sphingoglycolipid analogues
    Patent number: 10046046
    Abstract: The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: August 14, 2018
    Assignee: Victoria Link Limited
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, Gavin Frank Painter
  • Conjugate compounds
    Patent number: 9764037
    Abstract: The invention relates to sphingoglycolipid analogs and peptide derivatives thereof, which are useful in treating or preventing diseases or such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: September 19, 2017
    Assignee: Victoria Link Limited
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, David Samuel Larsen, Gavin Frank Painter, Franca Ronchese
  • Sphingoglycolipid analogues
    Patent number: 9717790
    Abstract: The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
    Type: Grant
    Filed: June 10, 2014
    Date of Patent: August 1, 2017
    Assignee: Victoria Link Limited
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, David Samuel Larsen, Gavin Frank Painter
  • AMINO SPHINGOGLYCOLIPID ANALOGUES
    Publication number: 20170119875
    Abstract: The invention relates to amino sphingoglycolipid analogues and peptide derivatives thereof, compositions comprising these compounds and methods of treating or preventing diseases or conditions using such compounds, especially diseases or conditions relating to cancer, infection, atopic disorders, autoimmune disease or diabetes.
    Type: Application
    Filed: June 5, 2015
    Publication date: May 4, 2017
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, Gavin Frank Painter
  • Organic compounds as proantigens for natural killer T cells
    Patent number: 9586985
    Abstract: This invention relates to sphingoglycolipid analogs, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection, atopic disorders, autoimmune disease, diabetes or cancer.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: March 7, 2017
    Assignee: VICTORIA LINK LIMITED
    Inventors: Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, David Samuel Larsen, Gavin Frank Painter, Regan J. Anderson
  • SPHINGOGLYCOLIPID ANALOGUES
    Publication number: 20160136267
    Abstract: The invention relates to sphingoglycolipid analogues which are useful in treating or preventing diseases and conditions such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
    Type: Application
    Filed: June 10, 2014
    Publication date: May 19, 2016
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, Karen Anne Johnston, David Samuel Larsen, Gavin Frank Painter
  • CONJUGATE COMPOUNDS
    Publication number: 20150352219
    Abstract: The invention relates to sphingoglycolipid analogues and peptide derivatives thereof, which are useful in treating or preventing diseases or such as those relating to infection, atopic disorders, autoimmune diseases or cancer.
    Type: Application
    Filed: December 6, 2013
    Publication date: December 10, 2015
    Inventors: Regan James Anderson, Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, David Samuel Larsen, Gavin Frank Painter, Franca Ronchese
  • ORGANIC COMPOUNDS
    Publication number: 20150191503
    Abstract: This invention relates to sphingoglycolipid analogues, compositions comprising these compounds, processes for preparing the compounds, and methods of treating or preventing diseases or conditions using the compounds, such as diseases or conditions relating to infection, atopic disorders, autoimmune disease, diabetes or cancer.
    Type: Application
    Filed: July 26, 2013
    Publication date: July 9, 2015
    Inventors: Benjamin Jason Compton, Colin Malcolm Hayman, Ian Francis Hermans, David Samuel Larsen, Gavin Frank Painter, Regan J. Anderson